8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 2, 2005

MIRAVANT MEDICAL TECHNOLOGIES

(Exact name of registrant as specified in its charter)

DELAWARE	0-25544	77-0222872
(State or other jurisdiction ofincorporation)	(Commission File Number)	(IRS Employer Identification No.)

336 Bollay Drive

Santa Barbara, CA 93117

(Address of principal executive offices, including zip code)

(805) 685-9880

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(d)On May 2, 2005, the board of directors of Miravant Medical Technologies, or the Company, appointed Nuno Brandolini, Kevin R. McCarthy and Rani Aliahmad as new directors to the board. The board has determined that each of Messrs. Brandolini, McCarthy and Aliahmad have been named to the board’s Audit and Compensation Committees. The composition of the Governance and Nominating Committee will be reconstituted following the annual meeting in June 2005. Messrs. Brandolini and McCarthy are general partners of Scorpion Capital Partners, LP., the lead investment group with which the Company recently completed a Series B Preferred Stock financing. Mr. Aliahmad was introduced to the Company by an investor.

A copy of the press release issued on May 3, 2005 by Miravant announcing the appointments of Messrs. Brandolini, McCarthy and Aliahmad to the board is attached hereto and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

ExhibitNo.	Description
99.1	Press Release dated May 3, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MIRAVANT MEDICAL TECHNOLOGIES
By:	/s/ John M. Philpott
	John M. Philpott Chief Financial Officer

Date: May 4, 2005

EXHIBIT INDEX

ExhibitNo.	Description
99.1	Press Release dated May 3, 2005

EX-99

Exhibit 99.1 Press Release

Nuno Brandolini, Kevin R. McCarthy and Rani Aliahmad Join Miravant Board of Directors

SANTA BARBARA, Calif.--(BUSINESS WIRE)--May 3, 2005--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), announced today the elections of Nuno Brandolini, Kevin R. McCarthy and Rani Aliahmad, to its board of directors.

Mr. Brandolini has been an investment banker with Lazard Freres & Co. and a principal with the Baltheus Group and Logic Capital, two venture capital firms. He was Vice President, Investment Banking at Salomon Brothers, Inc. and co-founded Rosecliff, Inc., a middle-market private equity fund, where he served as Managing Director until 1995. He also co-founded Independence Holdings, a $100 million private equity fund-of-funds, and Scorpion Holdings, a private equity firm. Mr. Brandolini currently serves as the General Partner of Scorpion Capital Partners, L.P., a $120 million Small Business Investment Company (SBIC) that he co-founded in 2004. He was awarded a law degree by the University of Paris, and received an M.B.A. from the Wharton School of Business. He currently serves as a director on the Boards of Cheniere Energy, Inc., WalkAbout Computers, Inc., and Wellpartner, Inc.

Mr. McCarthy served with Ernst & Young (and the predecessor firm Arthur Young & Co), beginning in the audit department and entrepreneurial services group, and most recently as a Partner in its M&A Due Diligence Group. He was the Corporate Controller of Vac-Hyd Corporation, a jet engine repair company and Chief Financial Officer at Rosecliff, Inc., a middle-market private equity fund. Mr. McCarthy also co-founded Independence Holdings and Scorpion Holdings and currently serves as the General Partner of Scorpion Capital Partners, L.P., which he co-founded in 2004. He received a B.S. in Accounting from Babson College and is a director on the Boards of WalkAbout Computers, Inc., and Wellpartner, Inc.

Mr. Aliahmad is President of USA Call, a provider of end-to-end mobile solutions. Previously he co-founded Cardionomics and led the effort to develop Embryonix, an embryonic stem cell research center. From 1998-2001, Mr. Aliahmad was co-founder and Chief Strategic Officer of eCandy, a B2B platform for the US confectionery industry and was Managing Director of CIC, a telecom investment and consulting company based in Paris, France. He received his BA in Economics from Yale University (1992) and MBA in Information Technology and Entrepreneurship from MIT (1996).

Gary S. Kledzik, PhD, chairman and chief executive officer, stated, "We are pleased to welcome these accomplished businessmen to Miravant's board of directors. They expand the experience and expertise of our Company."

About Miravant

Miravant Medical Technologies specializes in PhotoPoint(R) photodynamic therapy (PDT), developing photoreactive (light-activated) drugs to selectively target diseased cells and blood vessels. Miravant's primary areas of focus are ophthalmology and cardiovascular disease with new drugs in clinical and preclinical development. PHOTREX(TM) (rostaporfin), the Company's most advanced program, has received an FDA Approvable Letter as a treatment for wet age-related macular degeneration and a Special Protocol Assessment for a Phase III confirmatory clinical trial. Miravant's cardiovascular development program, supported by an investment from Guidant Corporation, focuses on life-threatening coronary artery diseases, with PhotoPoint MV0633 in advanced preclinical testing for atherosclerosis, vulnerable plaque and restenosis.

For more information, please visit our web site at: www.miravant.com